Prestigious international institutions have initiated robust psychedelic research programs. Does Australia risk being left behind if it doesn’t do the same? NDRI’s Adjunct Research Fellow Dr Stephen Bright shares his views.
We are in the midst of an international psychedelic science renaissance. Prestigious institutions such as Imperial College, UCLA, New York University and Johns Hopkins Medical School have initiated robust psychedelic research programs (Bright, Williams, & Caldicot, 2017). The classic psychedelic drugs being investigated include Lysergic Acid Diethylamide (LSD), psilocybin (the psychoactive chemical in ‘magic mushrooms’) and Dimethyltryptamine (DMT). This research is providing increasing evidence that psychedelics might be powerful therapeutic tools that could be harnessed in the treatment of depression, anxiety, trauma and substance use disorders (for review, see Bright & Williams, 2018; Nichols, 2016).
Image: Lindsay Cameron